These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 5077739)

  • 1. Development of large-scale fractionation methods. 3. Preparation of a factor VIII concentrate of intermediate-purity.
    James HL; Wickerhauser M
    Vox Sang; 1972; 23(5):402-12. PubMed ID: 5077739
    [No Abstract]   [Full Text] [Related]  

  • 2. Use of frozen cryoprecipitate for the preparation of clinical factor VIII concentrate.
    Sgouris JT; Wickerhauser M
    Transfusion; 1973; 13(6):399-404. PubMed ID: 4749642
    [No Abstract]   [Full Text] [Related]  

  • 3. Levels of hepatitis B antigen and isoagglutinins in clinical concentrates of factor VIII and prothrombin complex.
    Wickerhauser M
    Dev Biol Stand; 1974; 27():172-7. PubMed ID: 4463121
    [No Abstract]   [Full Text] [Related]  

  • 4. Factor VIII concentrate: what is "high purity"?
    Schoppmann A; Weber A; Hondl F; Linnau Y
    Thromb Haemost; 1994 Sep; 72(3):483-4. PubMed ID: 7855803
    [No Abstract]   [Full Text] [Related]  

  • 5. Hemophilia and von Willebrand's disease: 2. Management. Association of Hemophilia Clinic Directors of Canada.
    CMAJ; 1995 Jul; 153(2):147-57. PubMed ID: 7600466
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cryoprecipitate.
    Armstrong D
    S Afr Med J; 1975 Jul; 49(31):1245-7. PubMed ID: 1154189
    [No Abstract]   [Full Text] [Related]  

  • 7. Jaundice and hepatitis B antigen-antibody in hemophilia.
    Lewis JH; Maxwell NG; Brandon JM
    Transfusion; 1974; 14(3):203-11. PubMed ID: 4835949
    [No Abstract]   [Full Text] [Related]  

  • 8. Factor VIII fractionation on aminohexyl Sepharose with possible reduction in hepatitis B antigen.
    Austen DE; Smith JK
    Thromb Haemost; 1982 Aug; 48(1):46-8. PubMed ID: 6813994
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Zero incidence of inhibitors in previously untreated patients who received intermediate purity factor VIII concentrate or factor IX complex.
    Schimpf K; Schwarz P; Kunschak M
    Thromb Haemost; 1995 Mar; 73(3):553-5. PubMed ID: 7667845
    [No Abstract]   [Full Text] [Related]  

  • 10. Products for the treatment of hemophilia A and B prepared by ion exchange chromatography.
    Sultan Y; Boyeldieu D; Stieltjes N
    Nouv Rev Fr Hematol (1978); 1994; 36 Suppl 1():S59-60. PubMed ID: 8177717
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of the hemophiliac with anti-VIII.
    Lewis JH; Oskins PB
    Ann N Y Acad Sci; 1975 Jan; 240():407-11. PubMed ID: 1053885
    [No Abstract]   [Full Text] [Related]  

  • 12. [Biological control of substitution therapy in hemophilia A].
    Lisichkov T
    Vutr Boles; 1972; 11(5):103-7. PubMed ID: 4680013
    [No Abstract]   [Full Text] [Related]  

  • 13. Recent advances in hemophilia. Part III. Discussion paper: The Red Cross program.
    Greenwalt TJ
    Ann N Y Acad Sci; 1975 Jan; 240():208-12. PubMed ID: 1053865
    [No Abstract]   [Full Text] [Related]  

  • 14. Factor VIII concentrate prepared from DDAVP stimulated blood donor plasma.
    Nilsson IM; Walter H; Mikaelsson M; Vilhardt H
    Scand J Haematol; 1979 Jan; 22(1):42-6. PubMed ID: 424697
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Treatment with plasma concentrates in hemophilia A. State Security and Health Planning Office. Expert Panel].
    Sangre (Barc); 1994 Apr; 39(2):157-61. PubMed ID: 8059299
    [No Abstract]   [Full Text] [Related]  

  • 16. Factor VIII concentrate available for treatment of classical hemophilia.
    Jewett WR
    Ann N Y Acad Sci; 1975 Jan; 240():188-90. PubMed ID: 1053863
    [No Abstract]   [Full Text] [Related]  

  • 17. Letter: Treatment of inhibitors to factor VIII with activated prothrombin concentrate.
    Sultan Y; Brouet JC; Debre P
    N Engl J Med; 1974 Nov; 291(20):1087. PubMed ID: 4414451
    [No Abstract]   [Full Text] [Related]  

  • 18. [Cryoprecipitate should have preference over factor VIII concentrate in the treatment of patients with hemophilia A].
    Kunst VA; Nováková IR; Haanen C
    Ned Tijdschr Geneeskd; 1989 Jun; 133(23):1163-6. PubMed ID: 2501689
    [No Abstract]   [Full Text] [Related]  

  • 19. A therapeutic concentrate of coagulation factors II, IX and X from citrated, factor VIII-depleted plasma.
    Middleton SM; Bennett IH; Smith JK
    Vox Sang; 1973 May; 24(5):441-56. PubMed ID: 4691239
    [No Abstract]   [Full Text] [Related]  

  • 20. Production of cryoprecipitate of intermediate purity in a closed system thaw-siphon process.
    Mason EC; Pepper DS; Griffin B
    Thromb Haemost; 1981 Aug; 46(2):543-6. PubMed ID: 6795742
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.